|
IL-1R1, MMP-9, and EAE |
1R21AI169218-01 |
|
NIAID |
2022 |
|
Monitoring Treatment Efficacy in Leprosy |
1R21AI171254-01 |
|
NIAID |
2022 |
|
Allograft inflammatory factor-1 and immune tolerance |
1R21AI171739-01 |
|
NIAID |
2022 |
|
Novel Biofilm Paradigm Explaining Clinical Implant-Associated Illness. |
1R21AI171932-01 |
|
NIAID |
2022 |
|
B cell-targeted CAR-T treatment of CNS Autoimmunity |
1R21AI171994-01 |
|
NIAID |
2022 |
|
Human T cell Lymphotropic Virus Vaccine development |
1R41AI165061-01A1 |
|
NIAID |
2022 |
|
Nanoimmunotherapy for chronic immune-mediated diseases |
1R41AI170413-01 |
|
NIAID |
2022 |
|
Long non-coding RNA signatures to distinguish relapsing-remitting multiple sclerosis from primary progressive and secondary progressive multiple sclerosis |
1R43AI157674-01A1 |
|
NIAID |
2022 |
|
Novel immunotherapy against MOG antibody disease |
1R43AI172705-01 |
|
NIAID |
2022 |
|
Developing botanical-derived chemical tools for controlling mosquito vectors |
1R56AI158674-01A1 |
|
NIAID |
2022 |